| |
KRASPRO analysis set
|
PRO analysis set
|
|---|
|
WT KRAS(n = 76)a
|
MT KRAS(n = 54)a
|
Overall (n = 137)a
|
|---|
|
Baseline
|
Safety follow-up
|
Baseline
|
Safety follow-up
|
Baseline
|
Safety follow-up
|
|---|
|
Mean (SD) EQ-5D subscale
scores
b
|
|
Mobility
|
1.13 (0.34)
|
1.17 (0.38)
|
1.13 (0.34)
|
1.12 (0.42)
|
1.12 (0.33)
|
1.16 (0.41)
|
|
Self care
|
1.05 (0.23)
|
1.14 (0.35)
|
1.13 (0.44)
|
1.15 (0.51)
|
1.08 (0.32)
|
1.15 (0.43)
|
|
Usual activities
|
1.29 (0.56)
|
1.39 (0.60)
|
1.35 (0.59)
|
1.34 (0.65)
|
1.30 (0.56)
|
1.38 (0.62)
|
|
Pain/discomfort
|
1.45 (0.58)
|
1.53 (0.56)
|
1.53 (0.58)
|
1.46 (0.56)
|
1.46 (0.57)
|
1.51 (0.56)
|
|
Anxiety/depression
|
1.26 (0.50)
|
1.25 (0.44)
|
1.39 (0.49)
|
1.33 (0.48)
|
1.31 (0.49)
|
1.30 (0.46)
|
|
Mean (SD) QLQ-C30 functioning
scores
c
|
|
Physical
|
71.7 (20.1)
|
71.3 (20.5)d
|
71.9 (19.6)
|
78.6 (10.5)d
|
72.5 (19.8)
|
74.3 (18.2)d
|
|
Role
|
26.1 (33.4)
|
30.0 (33.3)
|
32.1 (35.0)
|
28.8 (29.8)
|
27.4 (33.7)
|
30.3 (31.2)
|
|
Cognitive
|
10.2 (17.7)
|
13.3 (19.7)
|
13.6 (22.7)
|
14.1 (18.2)
|
11.0 (19.6)
|
14.4 (19.6)
|
|
Emotional
|
24.3 (23.1)
|
22.1 (20.0)
|
26.5 (22.9)
|
14.9 (19.0)
|
24.6 (22.6)
|
19.8 (20.5)
|
|
Social
|
25.8 (33.4)
|
25.7 (27.8)
|
23.5 (32.6)
|
16.7 (21.2)
|
23.6 (32.5)
|
22.4 (24.9)
|
|
Mean (SD) QLQ-C30 symptom
scores
e
|
|
Fatigue
|
29.0 (27.8)
|
31.9 (28.3)
|
35.4 (31.6)
|
31.3 (22.6)
|
31.4 (28.8)
|
32.3 (26.0)
|
|
Pain
|
19.1 (27.4)
|
22.9 (27.4)
|
25.3 (29.6)
|
19.3 (26.1)
|
21.2 (27.9)
|
21.6 (26.6)
|
|
Nausea/vomiting
|
3.3 (10.6)
|
7.6 (14.2)
|
8.6 (19.1)
|
10.6 (19.9)
|
5.3 (14.6)
|
8.6 (16.8)
|
|
Mean (SD) QLQ-C30 single-item
scores
e
|
|
Dyspnoea
|
17.1 (27.5)
|
21.0 (28.1)
|
23.5 (30.8)
|
21.2 (21.8)
|
19.2 (28.5)
|
21.3 (26.4)
|
|
Insomnia
|
29.8 (35.8)
|
23.8 (28.7)
|
28.4 (32.0)
|
23.2 (27.0)
|
29.4 (34.2)
|
25.0 (28.9)
|
|
Appetite loss
|
18.9 (31.0)
|
15.2 (30.6)
|
25.9 (35.3)
|
15.2 (27.8)
|
20.7 (32.4)
|
14.4 (28.4)
|
|
Constipation
|
13.3 (23.2)
|
4.8 (14.3)
|
14.2 (25.6)
|
12.1 (23.3)
|
14.0 (23.8)
|
9.7 (22.0)
|
|
Diarrhoea
|
20.7 (30.6)
|
12.4 (23.0)
|
19.1 (30.8)
|
22.2 (27.2)
|
19.5 (30.0)
|
18.1 (25.6)
|
|
Financial impact
|
8.1 (20.5)
|
7.6 (18.2)
|
6.8 (17.6)
|
11.5 (26.2)
|
7.2 (18.8)
|
9.4 (22.0)
|
-
aActual ‘n’ number may differ according to subscale item and time point (data from fewer patients were available at safety follow-up vs. baseline); bHigher scores indicate a better level of functioning of a greater degree of symptomology depending on subscale; cA higher score indicates a better level of functioning/health; cA higher score indicates a better level of functioning/health; dData not available at safety follow-up, data reported at week 48 instead; eA higher score indicates a greater degree of symptomology.
